AbCellera Biologics Inc.
ABCL
Rank in Stocks
#4191
AbCellera Biologics Inc. specializes in pioneering an advanced platform for the... AbCellera Biologics Inc. specializes in pioneering an advanced platform for the discovery of antibodies. This comprehensive, AI-driven system meticulously explores and analyzes natural immune systems to identify antibodies suitable for the creation of new pharmaceutical drugs. As of December 31, 2021, the company had cultivated 156 discovery programs, ranging from completed to in-progress or under contract, in partnership with 36 entities. Notably, AbCellera maintains a crucial research collaboration and license agreement with Eli Lilly and Company. Founded in 2012, the firm is headquartered in Vancouver, Canada.
Share Price
$11.89
Market Cap
$3.85B
Change (1 day)
0.76%
Change (1 year)
112.70%
Country
CA
Trade AbCellera Biologics Inc. (ABCL)
Category
Healthcare
Earnings for AbCellera Biologics Inc. (ABCL)
Earnings in Jun 2026 TTM: $-196.77M
According to AbCellera Biologics Inc. latest financial reports the company's current earnings are $-196.77M. In 2023 the company made an earning of $-174.03M, a decrease compared to its 2022 earnings that were of $239.10M. The earnings displayed on this page are the earnings before interest and taxes or simply EBIT.
Earnings history for AbCellera Biologics Inc. from 2018 to 2026
Earnings at the end of each year
| Year | Earnings | Change |
|---|---|---|
| 2026 (TTM) | $-196.77M | -1.81% |
| 2024 | $-200.40M | 15.15% |
| 2023 | $-174.03M | -172.79% |
| 2022 | $239.10M | 9.10% |
| 2021 | $219.15M | 38.85% |
| 2020 | $157.83M | -7,238.53% |
| 2019 | $-2.21M | -815.53% |
| 2018 | $309.00K | 0.00% |
Earnings for similar companies or competitors
| Company | Earnings | Earnings Difference | Country |
|---|---|---|---|
| $5.27B | -2,780.76% |
US
|
|
| $-3.09B | 1,468.84% |
US
|
|
| $-4.02B | 1,941.07% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | -1,091.34% |
NL
|
